Management of atrial fibrillation in patients taking targeted cancer therapies

被引：24
作者：
Asnani A. [1 ]
Manning A. [2 ]
Mansour M. [3 ]
Ruskin J. [3 ]
Hochberg E.P. [4 ]
Ptaszek L.M. [3 ]
机构：
[1] Cardio-Oncology Program, Corrigan Minehan Heart Center, Massachusetts General Hospital, 149 13th Street, Room 4.302, Boston, 02129, MA
[2] Massachusetts General Hospital, Boston, 02129, MA
[3] Cardiac Arrhythmia Service, Corrigan-Minehan Heart Center, Massachusetts General Hospital, 55 Fruit Street, GRB 109, Boston, 02114, MA
[4] Hematology/Oncology, Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, MA
来源：
Cardio-Oncology | / 3卷 / 1期
关键词：
Anticoagulation; Atrial fibrillation; Cancer; Chemotherapy; Ibrutinib; Targed therapies;
D O I：
10.1186/s40959-017-0021-y
中图分类号：
学科分类号：
摘要：
Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, several drug-drug interactions have emerged that complicate the use of antiarrhythmic drugs (AADs) in patients with active malignancy. Moreover, specific targeted therapies such as ibrutinib may contribute directly to the development of AF. The decision to pursue systemic anticoagulation can be challenging in patients with malignancy due to a number of factors, including the need for frequent procedures, the presence of malignancy-related risk factors for bleeding, and limited data regarding the safety of the novel oral anticoagulants (NOACs) in cancer patients. This review describes the challenges associated with AF management in patients with cancer and highlights a number of important drug-drug interactions that can impact patient management. © 2017, The Author(s).
引用
收藏
相关论文
共 37 条
  • [1] Hu Y.F., Liu C.J., Chang P.M., Tsao H.M., Lin Y.J., Chang S.L., Lo L.W., Tuan T.C., Li C.H., Chao T.F., Et al., Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients, Int J Cardiol, 165, pp. 355-357, (2013)
  • [2] Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer D.E., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, JAMA, 285, pp. 2370-2375, (2001)
  • [3] Ostenfeld E.B., Erichsen R., Pedersen L., Farkas D.K., Weiss N.S., Sorensen H.T., Atrial fibrillation as a marker of occult cancer, PLoS One, 9, (2014)
  • [4] Conen D., Wong J.A., Sandhu R.K., Cook N.R., Lee I.M., Buring J.E., Albert C.M., Risk of malignant cancer among women with New-onset atrial fibrillation, JAMA Cardiol, 1, pp. 389-396, (2016)
  • [5] Rahman F., Ko D., Benjamin E.J., Association of atrial fibrillation and cancer, JAMA Cardiol, 1, pp. 384-386, (2016)
  • [6] Onaitis M., D'Amico T., Zhao Y., O'Brien S., Harpole D., Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database, Ann Thorac Surg, 90, pp. 368-374, (2010)
  • [7] Nojiri T., Inoue M., Maeda H., Takeuchi Y., Sawabata N., Shintani Y., Yamamoto K., Okumura M., Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery, Eur J Cardiothorac Surg, 44, pp. 98-103, (2013)
  • [8] Imperatori A., Mariscalco G., Riganti G., Rotolo N., Conti V., Dominioni L., Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study, J Cardiothorac Surg, 7, (2012)
  • [9] DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L., Alteri R., Robbins A.S., Jemal A., Cancer treatment and survivorship statistics, 2014, CA Cancer J Clin, 64, pp. 252-271, (2014)
  • [10] Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., Bauer J.A., Tchou P.J., Niebauer M.J., Natale A., Van Wagoner D.R., C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation, Circulation, 104, pp. 2886-2891, (2001)
1234